FOXO TECHNOLOGIES INC. — Form 8-K
Filed July 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
FOXO reported Q1 2026 net revenues of $5.1M (vs. $3.2M prior year) and reduced operating loss to $0.3M (vs. $1.5M prior year). The company effected a 1:3,000 reverse stock split and converted ~$7.8M in Series A Preferred Stock into non-convertible debt. CEO Seamus Lagan licensed the company's epigenetics IP to LongevityFP Technologies (owned by former CEO Jon Sabes) for a 3% royalty (capped at $1.3M) plus a 10-year option for majority ownership of FOXO Labs subsidiary, with FOXO retaining 40%. The company is exploring uplisting to NYSE American and considering acquisitions, including a potential $10M+ annual revenue deal in Vector BioSource's pharmaceutical biospecimen space.
Why this rating
Revenue growth and loss reduction are operationally positive, but company is micro-cap ($1.9M). Reverse split, debt conversion, and IP license to former CEO (with future dilution risk via option) create material strategic/control shifts relative to tiny equity base. Uplisting and acquisition pursuit add uncertainty.
See more from July 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.